Patient iP is an interconnected health information platform accelerating the provision of data insight needed for transformative research, development and market placement of new therapies.
The Patient iP Connected Site Network offers private-practice physicians the opportunity to align with established investigative research sites in order to link patients with new therapeutic offerings and derive greater revenue for their practices.
The Challenge with Traditional Research Recruitment
Recent study findings published by the Tufts Center for the Study of Drug Development revealed that 91% of physicians feel ‘somewhat’ or ‘very’ comfortable discussing the opportunity to participate in a clinical trial with patients, but these same providers only refer less than 0.2% of their patients into trials. Along those same lines, more than 80% of patients say they are willing to participate in clinical research studies, but only around 10% actually do.
These challenges stem from the fact that typically, patients must be receiving care at an investigative research site to be considered for trial enrollment. In reality, only a fraction of care providers – perhaps only one out of every eight – are registered as a 1572 primary investigator. The same holds true for the number of active research sites – a small number when compared with the total number of physician practices. Yet each year there are about one-billion office visits annually in the US, with nearly 100% of those being documented electronically via EMRs.
So couple an artificially limited pool of participants with increasing protocol complexity stemming from the burgeoning science of personalized medicine and it is no wonder that the vast majority of studies struggle to perform against enrollment objectives.
Shifting the Paradigm
There are currently about 100,000 trials underway in the US, each in need of a very specific patient population. And because each protocol can have anywhere between 10-50 eligibility criterion, site staff often lack the time to complete thorough chart reviews in response to initial feasibility questionnaires. Instead a best guess of how many patients match criteria is provided, setting a potentially unrealistic level of expectations.
Meanwhile, other organizations, both internal and external to a sponsor, rely on a cadre of tools to identify or recruit patients. These include traditional print and radio/TV advertising, referral networks, social media and other forms of outreach that are leveraged partially from pharmacy sales data and/or partially the result of patient self-identification. And while these later approaches may drive some degree of success, they typically fail to reach the consistently underserved research populations of both the elderly and non-Caucasian races.
In order to get more targeted traction with the millions of patients falling outside of the traditional site network and recruitment channels, sponsors are finally stepping outside of the ‘conventional’ approach of “site-based patient identification” and embracing EMR data and modern technology – analytics, natural language processing, risk stratification and more. The outcome? Patient-based site identification, an approach that is truly patient-centric and involves the caregivers that can help support the patient’s decision-making process around participation and affect adherence over the course of the trial.
Patient iP invites interested Aprima customers to join our Connected Site Network so that practice patients can take advantage of appropriate research opportunities, with minimal overhead and burden to the practice itself.